PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.24%
Revenue growth under 50% of CVE's 22.10%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-7.67%
Negative gross profit growth while CVE is at 63.62%. Joel Greenblatt would examine cost competitiveness or demand decline.
-12.05%
Negative EBIT growth while CVE is at 152.97%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-12.05%
Negative operating income growth while CVE is at 152.97%. Joel Greenblatt would press for urgent turnaround measures.
20.83%
Net income growth under 50% of CVE's 115.24%. Michael Burry would suspect the firm is falling well behind a key competitor.
9.63%
EPS growth under 50% of CVE's 117.78%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
9.70%
Diluted EPS growth under 50% of CVE's 120.45%. Michael Burry would worry about an eroding competitive position or excessive dilution.
9.74%
Slight or no buybacks while CVE is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
10.17%
Slight or no buyback while CVE is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-8.95%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
9.03%
OCF growth under 50% of CVE's 37.59%. Michael Burry might suspect questionable revenue recognition or rising costs.
-62.30%
Negative FCF growth while CVE is at 73.38%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
2.67%
10Y revenue/share CAGR under 50% of CVE's 20.82%. Michael Burry would suspect a lasting competitive disadvantage.
46.50%
5Y revenue/share CAGR at 50-75% of CVE's 66.12%. Martin Whitman would worry about a lagging mid-term growth trajectory.
111.30%
3Y revenue/share CAGR at 50-75% of CVE's 164.15%. Martin Whitman would question if the firm lags behind competitor innovations.
-47.72%
Negative 10Y OCF/share CAGR while CVE stands at 30.21%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-28.55%
Negative 5Y OCF/share CAGR while CVE is at 41.25%. Joel Greenblatt would question the firm’s operational model or cost structure.
74.44%
3Y OCF/share CAGR at 50-75% of CVE's 139.72%. Martin Whitman would suspect weaker recent execution or product competitiveness.
16.51%
Below 50% of CVE's 101.25%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
626.55%
5Y net income/share CAGR similar to CVE's 602.35%. Walter Schloss might see both on parallel mid-term trajectories.
125.34%
Below 50% of CVE's 715.77%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-4.80%
Negative equity/share CAGR over 10 years while CVE stands at 13.90%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
2.66%
5Y equity/share CAGR above 1.5x CVE's 0.49%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
108.34%
3Y equity/share CAGR above 1.5x CVE's 8.42%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-58.43%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
310.98%
5Y dividend/share CAGR above 1.5x CVE's 181.09%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
226.06%
3Y dividend/share CAGR of 226.06% while CVE is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
21.27%
AR growth well above CVE's 39.90%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
1.95%
Asset growth above 1.5x CVE's 1.27%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-6.57%
We have a declining book value while CVE shows 6.24%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.14%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-19.31%
We cut SG&A while CVE invests at 74.85%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.